Expression of the angiogenic mediator, angiopoietin-like 4, in the eyes of patients with proliferative sickle retinopathy

Kathleen Jee¹, Murilo Rodrigues¹, Fabiana Kashiwabuchi¹, Brooks P. Applewhite¹, Ian Han¹, Gerard Lutty¹, Morton F. Goldberg¹, Gregg L. Semenza², Silvia Montaner³, Akrit Sodhi¹*¹

1 Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, 2 Departments of Pediatrics, Medicine, Oncology, Radiation Oncology, Biological Chemistry, and Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America, 3 Department of Oncology and Diagnostic Sciences, School of Dentistry; Department of Pathology, School of Medicine; Greenbaum Cancer Center, University of Maryland, Baltimore, MD, United States of America

* asodhi1@jhmi.edu

Abstract

The recent success of therapies directly targeting the angiogenic mediator, vascular endothelial growth factor (VEGF), for the treatment of proliferative diabetic retinopathy has encouraged clinicians to extend the use of anti-VEGF therapies for the treatment of another ischemic retinal vascular disease, proliferative sickle cell retinopathy (PSR), the most common cause of irreversible blindness in patients with sickle cell disease. However, results from case reports evaluating anti-VEGF therapies for PSR have been mixed. This highlights the need to identify alternative therapeutic targets for the treatment of retinal neovascularization in sickle cell patients. In this regard, angiopoietin-like 4 (ANGPTL4) is a novel angiogenic factor regulated by the transcription factor, hypoxia-inducible factor 1, the master regulator of angiogenic mediators (including VEGF) in ischemic retinal disease. In an effort to identify alternative targets for the treatment of sickle cell retinopathy, we have explored the expression of ANGPTL4 in the eyes of patients with PSR. To this end, we examined expression and localization of ANGPTL4 by immunohistochemistry in autopsy eyes from patients with known PSR (n = 5 patients). Complementary studies were performed using enzyme-linked immunosorbent assays in aqueous (n = 8; 7 patients, 2 samples from one eye of same patient) and vitreous (n = 3 patients) samples from a second group of patients with active PSR. We detected expression of ANGPTL4 in neovascular tissue and in the ischemic inner retina in PSR, but not control, eyes. We further observed elevated expression of ANGPTL4 in the aqueous and vitreous of PSR patients compared to controls. These results suggest that ANGPTL4 could contribute to the development of retinal neovascularization in sickle cell patients and could therefore be a therapeutic target for the treatment of PSR.
Introduction
Sickle cell disease is the most prevalent genetic hematologic disorder in the United States, disproportionately affecting African Americans[1]. Sickle cell patients who are homozygous for Hb S or who are heterozygous for Hb S and either Hb C or β-thalassemia are all at increased risk for vascular occlusions in the retina. These vaso-occlusions most often occur in the small vessels of the peripheral retina, can cause tissue ischemia[2, 3], and can lead to the development of retinal neovascularization (NV)[4]. These so-called neovascular “sea fan” lesions indicate presence of proliferative sickle retinopathy (PSR), the leading cause of vision loss in sickle cell patients[5, 6].

Scatter laser photocoagulation is the most commonly used intervention for PSR, with the long-term goal of preventing vision loss from a vitreous hemorrhage or a retinal detachment[7]. Scatter laser has been successfully used for the treatment of other ischemic retinopathies, most notably proliferative diabetic retinopathy (PDR)[8], retinopathy of prematurity (ROP)[9], and ischemic retinal vein occlusions (RVOs)[10]; nonetheless, clinical trials have not demonstrated a clear benefit for scatter laser in the treatment of retinal NV in sickle cell patients[11, 12]. Indeed, scatter laser leads to complete regression of only one-third of pre-existing retinal NV sea fans, a rate similar to their rate of spontaneous regression. Presently, reasonable disagreement exists as to whether (and when) treatment of NV in sickle cell patients with scatter laser results in better outcomes than observation alone[7], prompting exploration of other treatment options.

In this regard, we have recently demonstrated that expression of a hypoxia-regulated angiogenic factor, angiopoietin-like 4 (ANGPTL4)[13], is markedly increased in the eyes of patients with PDR[14, 15]. Like vascular endothelial growth factor (VEGF), we observed that ANGPTL4 expression is regulated by the transcription factor, hypoxia-inducible factor 1 (HIF-1), the master regulator of vasoactive factors in the ischemic retina [15]. We have further observed in pre-clinical studies that therapies targeting ANGPTL4 may augment therapies targeting vascular endothelial growth factor (VEGF) in treating retinal NV in the setting of PDR[14]. We hypothesize that ANGPTL4 may similarly contribute to the development of retinal NV in sickle cell patients. To interrogate this hypothesis, we have examined the expression of ANGPTL4 in the eyes of patients with PSR.

Materials and methods
Autopsy eyes
Institutional Review Board approval from the Johns Hopkins University School of Medicine was obtained for all autopsy eyes used in this study. 5 eyes from 5 sickle cell patients (documented by hemoglobin electrophoresis) with a history of untreated PSR (i.e., no history of scatter laser photocoagulation or prior intravitreal anti-VEGF therapy), and no known history of diabetes or ischemic retinal disease were selected for examination.

Hematoxylin and Eosin (H&E) staining
After deparaffinization and hydration, tissue sections were stained with Harris hematoxylin (Polysciences Inc, Warrington, PA) for 20 seconds. The sections were then washed in distilled water, stained with lithium carbonate, rinsed in distilled water, and then stained in 0.5% alcoholic eosin (Polysciences Inc.). After dehydrating sections with xylene, cover slips were secured with Permount (Fisher Scientific, Waltham, MA).

Immunohistochemistry
Immunohistochemical detection of ANGPTL4 (1:400 dilution; Abcam, Cambridge, MA) and CD34 (1:500 dilution; Covance, Princeton, NJ) was performed in paraffin-embedded tissue...
sections using premixed biotinylated anti-rabbit, anti-mouse and anti-goat immunoglobulins in phosphate buffered saline (PBS) from an ABC system (Dako, Santa Clara, CA) performed according to the manufacturer’s protocols as previously described[16, 17]. All immunohistochemical reagents, including antibodies, were identical for all specimens. Images were captured by scanning slides using the Aperio ScanScope program on Aperio Scanscope XT® System (Leica Biosystems, Wetzlar, Germany).

Aqueous and vitreous samples

Institutional Review Board approval from the Johns Hopkins University School of Medicine (Baltimore, MD) was obtained for all patient samples used in this study (NA_00084367, NA_00073289, and NA_00071340). Inclusion criteria for PSR and PDR patients included a known diagnosis of sickle cell disease (by hemoglobin electrophoresis) or diabetes, respectively, and the presence of active retinal neovascularization (observed on clinical exam or fluorescein angiography). Exclusion criteria for control patients included diabetes, sickle cell disease, or any ischemic retinal disease. Exclusion criteria for all patients included any other ischemic retinal disease, uveitis, retinal detachment within 1 year of sample collection, or neovascularization from another cause. Ocular samples were collected from consenting patients at the Wilmer Eye Institute undergoing intravitreal injection for active neovascularization (aqueous samples for PSR or PDR eyes), cataract surgery (aqueous samples for control eyes), or vitrectomy surgery for non-clearing vitreous hemorrhage (vitreous biopsies). Aqueous samples were obtained immediately after performing intravitreal injection or immediately prior to initiating cataract surgery (using a 30 gauge needle). Undiluted vitreous biopsies were obtained at the beginning of vitrectomy surgery. Consent was written and voluntary without stipend. Aqueous samples were immediately processed and stored at -80°C prior to analysis. Vitreous samples were immediately centrifuged at 16,000 x g for 5 min at 4°C, and then the supernatant was stored at -80°C prior to analysis.

ELISA

ANGPTL4 (DuoSet) and VEGF (Quantikine) ELISA kits were purchased from R&D Systems (Minneapolis, MN). Aqueous and vitreous were analyzed for ANGPTL4 (10 μL of aqueous diluted 1:10, 100 μL of undiluted vitreous) and VEGF (10 μL of aqueous or vitreous diluted 1:10) with ELISAs, performed according to the manufacturer’s protocols as previously described [14]. All ELISAs were performed in duplicate and quantitation was performed using the standard curve included in the kit.

Statistical analysis

We estimated that the minimum biologically- (and clinically-) relevant increase of ANGPTL4 in PSR patients, compared to control patients (without ischemic retinal disease or NV from another cause), would be a 2-fold increase. For power calculations, our pilot studies demonstrated that aqueous and vitreous concentrations of ANGPTL4 are approximately 2 ng/mL in non-diabetic control patients. To detect a biologically relevant increase in the levels of ANGPTL4 in patients with PSR, we assigned \( \mu_1 = [\text{ANGPTL4}] \) in PSR patients = 4 ng/mL; \( \mu_2 = [\text{ANGPTL4}] \) in control patients = 2 ng/mL; and the common standard deviation for \( [\text{ANGPTL4}] \) in control patients, \( \Sigma = 0.8 \). Importantly, the latter takes into account the impact of the typical biological variability observed in biological samples (i.e., \( \Sigma = \text{standard deviation} \)). For \( \alpha = 0.05 \) and power = 0.80, we calculated that we would need a minimum of 3 PSR patients to sufficiently power our study to observe a statistically significant, biologically-relevant increase in ANGPTL4 in PSR eyes.
Results from clinical samples are shown as mean ± SD. Statistical differences between groups were determined by one-way ANOVA and Holm-Sidak’s multiple comparisons tests. Correlations were tested using the Pearson method. Statistical analyses were performed using Prism 6.0 software (GraphPad).

Results

ANGPTL4 is expressed in retinal NV tissue in PSR eyes

To evaluate the expression of the HIF-regulated angiogenic mediator, ANGPTL4, in the eyes of patients with known PSR, we examined 5 paraffin-embedded autopsy eyes from 5 non-diabetic patients with sickle cell disease with untreated PSR (i.e., no prior history of scatter laser photoocoagulation or intravitreal anti-VEGF therapy), and no history of another ischemic retinal disease. We focused on areas of the peripheral retina anterior to the margin between perfused and non-perfused retina, as we have recently reported that VEGF and the α-subunit of HIF-1, the transcription factor that regulates its expression, are expressed in the peripheral ischemic retina in this region in PSR eyes[17]. We have also previously demonstrated that ANGPTL4 expression is regulated by HIF-1 in diabetic eye disease[13–15] as well as in the intraocular tumor, uveal melanoma[18], similar to VEGF. We observed strong expression of ANGPTL4 in the vascular endothelial cells lining neovascular sea fans (highlighted by expression of the endothelial cell marker, CD34) as well as in the stroma of the fibrovascular tissue in this region in 5/5 PSR eyes examined (Fig 1 and S1 Fig). We further observed expression of ANGPTL4 within the ischemic inner and outer retinal cells underlying the neovascular sea fans (Fig 1 and S2 Fig).

ANGPTL4 is expressed in the peripheral ischemic retina distant from retinal NV in PSR eyes

We have previously reported that HIF-1α and VEGF are also expressed in the peripheral ischemic retina in regions without active NV in PSR eyes[17]. We therefore examined expression of ANGPTL4 in the ischemic peripheral retina of autopsy eyes from patients with sickle cell retinopathy in regions without active NV. We observed an absence of vascular structures, highlighted by the absence of expression of the endothelial cell-specific antigen, CD34, in the peripheral retina of 5/5 eyes with PSR. Within these regions of ischemic retina, we detected strong expression of ANGPTL4 in the inner retina (Fig 2). Importantly, we did not detect any expression of ANGPTL4 in the inner retina in the posterior, perfused regions of these same eyes (Fig 2).

ANGPTL4 expression is increased in the aqueous of patients with active PSR

To determine whether secreted levels of ANGPTL4 are increased in the eyes of patients with PSR, we examined aqueous samples from 7 patients (8 samples total; 2 samples were obtained from the same patient at two different times during separate surgeries) with PSR (Table 1) for levels of ANGPTL4. The variability of the aqueous levels of both ANGPTL4 and VEGF was similar and represents the typical variability observed in biological samples. VEGF expression in the aqueous of PSR eyes (0.38±0.22 ng/mL; mean±SD) was increased 2.4-fold compared to control eyes (0.16±0.04 ng/mL) (Fig 3A). We similarly observed a marked increase in the expression of ANGPTL4 in the aqueous of PSR eyes (16.24±22.25 ng/mL) compared to control eyes (2.57±0.62 ng/mL) (6.3-fold; Fig 3B). ANGPTL4 levels were elevated in 8/8 aqueous samples from PSR patients, compared to the average ANGPTL4 level in control patients. These results were comparable to the increased expression of ANGPTL4 observed in the aqueous of patients with PDR (10.7-fold) (Fig 3B).
There was a trend toward a positive correlation between the aqueous levels of ANGPTL4 and the aqueous levels of VEGF in PSR patients ($r = 0.65$, $p = 0.078$) (Fig 3C); however, this correlation was not statistically significant. There was no correlation between ANGPTL4 and VEGF aqueous levels in patients with PDR ($r = -0.60$, $p = 0.29$) or in non-diabetic control patients ($r = 0.19$, $p = 0.49$; Fig 3C).

**ANGPTL4 expression is increased in the vitreous of patients with active PSR**

Motivated by these promising results, we performed vitreous biopsies on sickle cell patients with active NV undergoing vitrectomy surgery (Table 2), and examined the expression of ANGPTL4 compared to control patients. Again, the variability of the vitreous levels of ANGPTL4 expression in proliferative sickle retinopathy

Fig 1. Expression of ANGPTL4 in the peripheral ischemic inner retina and within adjacent retinal neovascular tissue of PSR eyes. (A) H&E staining of proliferative vessels (red arrows) observed on the surface of the peripheral retina of a PSR eye. (B) Non-staining IgG (negative control). (C) CD34 staining (vascular endothelial cells) of proliferative vessels (red arrows) overlying non-perfused (i.e., no CD34 staining of retinal vessels) peripheral retina (blue arrows). (D) ANGPTL4 staining within non-perfused (i.e., no CD34 staining of retinal vessels) peripheral retina (orange arrows) and in the vascular endothelial cells and within the stroma (red arrows) of the retinal neovascular tissue overlying the peripheral non-perfused retina. Similar results were obtained in 5/5 PSR eyes tested.

https://doi.org/10.1371/journal.pone.0183320.g001
ANGPTL4 and VEGF were similar and represents the typical variability observed in biological samples. The average for the vitreous VEGF levels in PSR (1.02±1.10 ng/mL) was increased compared to control patients (0.02±0.03 ng/mL), as has been previously published[19] (Fig 4A). However, this difference was not statistically significant. We did observe elevated levels of ANGPTL4 in the vitreous of 3/3 PSR patients (10.76±7.23 ng/mL) compared to non-diabetic control patients (1.88±1.06 ng/mL) (Fig 4B). Importantly, this increase was statistically significant (p<0.05). The levels of ANGPTL4 in the vitreous of PSR patients were between 3.4- and 10.1-fold higher than the average level in the vitreous of non-diabetic controls. Although the number of patients was small, there was a trend toward a positive correlation between the vitreous levels of ANGPTL4 and the vitreous levels of VEGF in PSR patients (r = 0.97, p = 0.14) (Fig 4C). Similar to the aqueous levels, there was no correlation between ANGPTL4 and VEGF vitreous levels in patients with PDR (r = -0.37, p = 0.54) or in non-diabetic control patients (Fig 4C).

**Discussion**

The rationale for the use of scatter laser photocoagulation in PSR patients is supported by the successful use of this approach for treatment of neovascularization in PDR[8], ROP[9], and ischemic RVOs[10]. However, clinical trials for PSR patients have not demonstrated better outcomes for scatter laser photocoagulation than observation alone[7], encouraging clinicians to explore other treatment options. An emerging, alternative approach to scatter laser photocoagulation for the treatment of retinal NV is the direct inhibition of the secreted mediators that promote pathological angiogenesis. In a recent multi-center randomized clinical trial, for
example, it was demonstrated that anti-VEGF therapy may be as effective as PRP for the treatment of patients with PDR[20]. We have previously reported that HIF-1α and VEGF are expressed in ischemic retinal tissue and overlying neovascular sea fans in PSR eyes, similar to PDR[17]. These results support the use of therapies targeting VEGF to treat retinal neovascularization in PSR patients.

The use of anti-VEGF therapy for PSR has been reported in only a handful of case reports, the results of which have varied[21–24]. Moreover, frequent hospitalizations for sickle cell crises, combined with development of PSR at a young age, may make PSR patients poor candidates for a therapy that may require long-term treatment with frequent (e.g., monthly) intravitreal injections. Whether short-term treatment with anti-VEGF therapy promotes auto-

| Table 1. Patient aqueous samples. |
|-----------------------------------|
| Patient | Age (years) | Sex | Phakic Status* | Prior Vitrectomy | Prior Laser | Genotype | DM Type | DM Duration (years) | CVD |
|---------|-------------|-----|---------------|-----------------|-------------|-----------|---------|-------------------|-----|
| Control |             |     |               |                 |             |           |         |                   |     |
| 1       | 72          | F   | P             | No              | No          | –         | –       | –                 | No  |
| 2       | 75          | F   | P             | No              | No          | –         | –       | –                 | Yes |
| 3       | 68          | F   | P             | No              | No          | –         | –       | –                 | Yes |
| 4       | 49          | F   | P             | No              | No          | –         | –       | –                 | Yes |
| 5       | 76          | F   | P             | No              | No          | –         | –       | –                 | Yes |
| 6       | 83          | M   | P             | No              | No          | –         | –       | –                 | Yes |
| 7       | 71          | F   | P             | No              | No          | –         | –       | –                 | Yes |
| 8       | 61          | M   | P             | No              | No          | –         | –       | –                 | No  |
| 9       | 73          | M   | P             | No              | No          | –         | –       | –                 | No  |
| 10      | 60          | F   | P             | No              | No          | –         | –       | –                 | No  |
| 11      | 54          | F   | P             | No              | No          | –         | –       | –                 | No  |
| 12      | 75          | F   | P             | No              | No          | –         | –       | –                 | Yes |
| 13      | 57          | F   | P             | No              | No          | –         | –       | –                 | No  |
| 14      | 64          | F   | P             | No              | No          | –         | –       | –                 | No  |
| 15      | 85          | F   | P             | No              | No          | –         | –       | –                 | Yes |

| PSR     |             |     |               |                 |             |           |         |                   |     |
|---------|-------------|-----|---------------|-----------------|-------------|-----------|---------|-------------------|-----|
| 1       | 39          | M   | P             | No              | No          | Unknown  | –       | –                 | No  |
| 2       | 58          | M   | P             | No              | Yes         | SS       | –       | –                 | Yes |
| 3       | 54          | M   | P             | Yes             | Yes         | SC       | –       | –                 | Yes |
| 4       | 54          | M   | P             | Yes             | Yes         | SC       | –       | –                 | No  |
| 5       | 80          | F   | PP            | Yes             | Yes         | AS       | II      | 20                | Yes |
| 6       | 32          | M   | P             | No              | Yes         | SC       | –       | –                 | No  |
| 7       | 52          | F   | P             | No              | Yes         | SC       | –       | –                 | No  |
| 8       | 37          | F   | P             | No              | Yes         | SS       | –       | –                 | Yes |

| PDR     |             |     |               |                 |             |           |         |                   |     |
|---------|-------------|-----|---------------|-----------------|-------------|-----------|---------|-------------------|-----|
| 1       | 50          | M   | P             | No              | No          | –         | I       | 15                | Yes |
| 2       | 52          | M   | PP            | No              | No          | –         | II      | Unknown           | Yes |
| 3       | 56          | F   | P             | No              | Yes         | –         | II      | 15                | Yes |
| 4       | 57          | M   | P             | No              | Yes         | –         | II      | 30                | Yes |
| 5       | 52          | M   | P             | No              | Yes         | –         | II      | 12                | No  |

* At time of sample collection.

P, phakic. PP, pseudophakic. DM, diabetes mellitus. CVD, cardiovascular disease. PSR, proliferative sickle retinopathy. PDR, proliferative diabetic retinopathy. SS, homozygous for the hemoglobin S mutation. SC, heterozygous for the hemoglobin S and C mutation. AS, sickle cell trait.

§Sample from one eye of same patient.

https://doi.org/10.1371/journal.pone.0183320.t001
infarction of NV in a subset of PSR patients who would otherwise progress without treatment, remains unexamined.

One explanation for the infrequent efficacy of anti-VEGF therapy in PSR patients is the potential contribution of other angiogenic mediators to the development of retinal NV in these patients. In this regard, post hoc analyses of studies examining the role of anti-VEGF therapies in diabetic eye disease suggest that monthly anti-VEGF treatment may not be adequate to prevent the progression of diabetic retinopathy in all treated patients\[25, 26\]; this is consistent with a role for other angiogenic mediators in the pathogenesis and progression of diabetic eye disease. In this regard, in a preclinical study, we recently provided evidence
supporting a role for neutralizing antibodies targeting ANGPTL4 in the treatment of PDR[14, 15]. Collectively, these observations suggest that therapies targeting secreted factors (in addition to VEGF) may be more effective than targeting only VEGF to treat retinal NV in patients with ischemic retinopathies.

Here we have demonstrated that ANGPTL4 is expressed in retinal neovascular sea fans and in the underlying ischemic inner retina in eyes with active PSR. We further report that the inner retina, in regions not immediately adjacent to neovascular sea fans, also demonstrates expression of ANGPTL4. Although increased expression of ANGPTL4 does not necessarily mean that this angiogenic mediator plays a pathologic role in PSR, our results provide a foundation for future studies examining the contribution of ANGPTL4 to the development of retinal NV in PSR patients. We speculate that expression of ANGPTL4 and VEGF at sites distal from sea fans may be sufficient to promote their survival following localized (sectoral) scatter laser. If this is correct, then more broad application of scatter laser photocoagulation, including circumferential scatter laser, would be required to quench the expression of these angiogenic mediators and treat patients with PSR[17].

Although not statistically significant, the trend toward a positive correlation between aqueous and vitreous levels of VEGF and ANGPTL4 in PSR eyes suggests that increased expression of one may predict increased expression of the other. We speculate that in eyes in which both angiogenic mediators are elevated and contribute to the survival of retinal NV, therapies targeting only one of these factors may not be sufficient to adequately promote the regression of neovascular sea fans in PSR patients. An alternative approach would be to simultaneously target ANGPTL4 and VEGF, either by combining current anti-VEGF therapies with those that directly inhibit ANGPTL4 or by directly inhibiting the transcription factor, HIF-1, thereby

Table 2. Patient vitreous samples.

| Patient | Age (years) | Sex | Phakic Status* | Prior Vitrectomy | Prior Laser | Genotype | DM Type | DM Duration (years) | CVD |
|---------|-------------|-----|----------------|-------------------|-------------|-----------|---------|---------------------|-----|
| **Control** | | | | | | | | | |
| 1 | 70 | M | P | No | No | – | – | – | Yes |
| 2 | 62 | F | PP | Yes | No | – | – | – | No |
| 3 | 70 | M | PP | No | No | – | – | – | Yes |
| 4 | 47 | F | P | No | No | – | – | – | No |
| 5 | 86 | F | PP | No | No | – | – | – | Yes |
| 6 | 72 | M | PP | No | No | – | – | – | Yes |
| 7 | 55 | M | P | No | No | – | – | – | No |
| 8 | 46 | M | PP | No | No | – | – | – | Yes |
| **PSR** | | | | | | | | | |
| 1 | 54 | M | P | Yes | Yes | SC | – | – | Yes |
| 2 | 52 | F | P | No | Yes | SC | – | – | No |
| 3 | 37 | F | P | No | Yes | SS | – | – | No |
| **PDR** | | | | | | | | | |
| 1 | 50 | M | P | No | No | – | I | 15 | Yes |
| 2 | 52 | M | PP | No | No | – | II | Unknown | Yes |
| 3 | 56 | F | P | No | Yes | – | II | 15 | Yes |
| 4 | 57 | M | P | No | Yes | – | II | 30 | Yes |
| 5 | 52 | M | P | No | Yes | – | II | 12 | No |

* At time of sample collection.

P, phakic. PP, pseudophakic. DM, diabetes mellitus. CVD, cardiovascular disease. PSR, proliferative sickle retinopathy. PDR, proliferative diabetic retinopathy. SC, heterozygous for the hemoglobin S and C mutation. SS, homozygous for the hemoglobin S mutation.

https://doi.org/10.1371/journal.pone.0183320.t002
blocking expression of VEGF and ANGPTL4, as well as additional angiogenic factors regulated by HIF-1 (Fig 5).

Strengths of this study include the qualitative assessment of ANGPTL4 expression in autopsy eyes from patients with PSR, combined with the quantitative assessment of ANGPTL4 in aqueous and vitreous samples from a separate group of sickle cell patients with active PSR (compared to non-sickle cell, non-diabetic control patients). Limitations of this study include the study size. To calculate the sample size for our studies, we assumed the minimum biologically- (and clinically-) relevant increase of ANGPTL4 in the aqueous or vitreous of PSR patients as compared to control patients, would be 2-fold. The number of samples included in our study met or exceeded the sample size that we calculated would be necessary to detect a

Fig 4. VEGF and ANGPTL4 expression in the vitreous of patients with active PSR. (A and B) Vitreous levels of VEGF (vVEGF) (A) and ANGPTL4 (vANGPTL4) (B) were measured in patients with active PSR and compared to control patients, as well as patients with active PDR. (C) Correlation between vVEGF and vANGPTL4 in control, PSR, and PDR patients. Control: non-diabetic, non-sickle cell patients; PDR: patients with active PDR. Vitreous levels of ANGPTL4 and VEGF are reported as concentration (ng/mL) or fold induction (compared to the average level for non-diabetic, non-sickle cell control patients, arbitrarily assigned as 1). NS = not significant; * p < 0.05; **** p < 0.0001.

https://doi.org/10.1371/journal.pone.0183320.g004
statistically significant, biologically-relevant increase in ANGPTL4 in PSR patients, as compared to control patients. Indeed, we did detect a statistically significant increase in ANGPTL4 in both the aqueous and vitreous of PSR patients. Interestingly, we did not detect a similar statistically significant increase in VEGF in the vitreous of PSR (or PDR) patients; this is likely a consequence of the higher variability of the aqueous and vitreous concentrations of VEGF compared to ANGPTL4. In light of the poor response of PSR to current treatment options (including the limited case reports assessing the effects of anti-VEGF therapy in PSR patients), this study provides the groundwork for future studies to assess the relative contribution of ANGPTL4 to the development of pathological angiogenesis in PSR eyes.

**Supporting information**

S1 Fig. High magnification images demonstrating expression of ANGPTL4 in the peripheral ischemic inner retina and within adjacent retinal neovascular tissue of PSR eyes. (A)
H&E staining of proliferative vessels (red arrows) observed on the surface of the peripheral retina of a PSR eye. (B) Non-staining IgG (negative control). (C) CD34 staining (vascular endothelial cells) of proliferative vessels (red arrows) overlying non-perfused (i.e., no CD34 staining of retinal vessels) peripheral retina (blue arrows). (D) ANGPTL4 staining within non-perfused (i.e., no CD34 staining of retinal vessels) peripheral retina (orange arrows) and in the vascular endothelial cells and within the stroma (red arrows) of the retinal neovascular tissue overlying the peripheral non-perfused retina.

(TIF)

S2 Fig. High magnification images demonstrating expression of ANGPTL4 in the inner retina and within adjacent retinal neovascular tissue of PSR eyes. ANGPTL4 staining within inner retinal cells as well as in the vascular endothelial cells and within the stroma of the retinal neovascular tissue.

(TIF)

Acknowledgments
The authors would like to thank Drs. Howard Ying, Sharon Solomon, James Handa, and Adrienne Scott for providing aqueous and vitreous samples for this study. This work was supported by the National Eye Institute, National Institutes of Health Grant, K08-EY021189 (AS), and an Unrestricted Grant from Research to Prevent Blindness (AS). Dr. Sodhi gratefully acknowledges the support he receives as a Special Scholar Award recipient from Research to Prevent Blindness, Inc.

Akrit Sodhi is the guarantor of this work and, as such, had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Author Contributions
Data curation: Kathleen Jee, Murilo Rodrigues.
Formal analysis: Kathleen Jee, Murilo Rodrigues, Akrit Sodhi.
Funding acquisition: Akrit Sodhi.
Investigation: Kathleen Jee, Murilo Rodrigues, Fabiana Kashiwabuchi, Brooks P. Applewhite, Ian Han.
Methodology: Akrit Sodhi.
Project administration: Akrit Sodhi.
Resources: Akrit Sodhi.
Supervision: Akrit Sodhi.
Validation: Kathleen Jee, Murilo Rodrigues, Akrit Sodhi.
Visualization: Kathleen Jee, Murilo Rodrigues, Akrit Sodhi.
Writing – original draft: Akrit Sodhi.
Writing – review & editing: Kathleen Jee, Murilo Rodrigues, Gerard Lutty, Morton F. Goldberg, Gregg L. Semenza, Silvia Montaner.

References
1. Bender MA, Douthitt Seibel G. Sickle Cell Disease. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, et al., editors. GeneReviews(R). Seattle (WA)1993.
2. Goldberg MF. Retinal vaso-occlusion in sickling hemoglobinopathies. Birth Defects Orig Artic Ser. 1976; 12(3):475–515. Epub 1976/01/01. PMID: 782601.

3. McLeod DS, Goldberg MF, Lutty GA. Dual-perspective analysis of vascular formations in sickle cell retinopathy. Arch Ophthalmol. 1993; 111(9):1234–45. Epub 1993/09/01. PMID: 8363467.

4. Goldberg MF. Retinal neovascularization in sickle cell retinopathy. Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol. 1977; 83(3 Pt 1):OP409–31. Epub 1977/05/01. PMID: 329529.

5. Cohen SB, Fletcher ME, Goldberg MF, Jednock NJ. Diagnosis and management of ocular complications of sickle hemoglobinopathies: Part V. Ophthalmic Surg. 1986; 17(6):369–74. Epub 1986/06/01. PMID: 2426644.

6. Goldberg MF. Classification and pathogenesis of proliferative sickle retinopathy. Am J Ophthalmol. 1971; 71(3):649–65. Epub 1971/03/01. PMID: 5546311.

7. Myint KT, Sahoo S, Thein AW, Moe S, Ni H. Laser therapy for retinopathy in sickle cell disease. Cochrane Database Syst Rev. 2015; 10:CD010790. Epub 2015/10/10. https://doi.org/10.1002/14651858.CD010790.pub2 PMID: 26451693.

8. Bressler NM, Beck RW, Ferris FL 3rd. Panretinal photocoagulation for proliferative diabetic retinopathy. N Engl J Med. 2011; 365(16):1520–6. https://doi.org/10.1056/NEJMoa1009352 PMID: 22401918.

9. Hellstrom A, Smith LE, Dammann O. Retinopathy of prematurity. Lancet. 2013; 382(9902):1445–57. https://doi.org/10.1016/S0140-6736(13)60179-6 PMID: 23782866; PubMed Central PMCID: PMCPMC4389630.

10. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol. 2012; 23(3):175–81. https://doi.org/10.1097/COI.0b013e3283524148 PMID: 22450223.

11. Farber MD, Jampol LM, Fox P, Moriarty BJ, Acheson RW, Rabb MF, et al. A randomized clinical trial of scatter photocoagulation of proliferative sickle cell retinopathy. Arch Ophthalmol. 1991; 109(3):363–7. Epub 1991/03/01. PMID: 2003796.

12. Jampol LM, Farber M, Rabb MF, Serjeant G. An update on techniques of photocoagulation treatment of proliferative sickle cell retinopathy. Eye (Lond). 1991; 5(Pt 2):260–3. Epub 1991/01/01. https://doi.org/10.1038/eye.1991.41 PMID: 2070884.

13. Xin X, Rodrigues M, Umapathi M, Kashiwabuchi F, Ma T, Babapoor-Farrokhran S, et al. Hypoxic retinal Muller cells promote vascular permeability by HIF-1-dependent up-regulation of angiopoietin-like-4. Proc Natl Acad Sci U S A. 2013; 110(36):E3425–34. Epub 2013/06/21. https://doi.org/10.1073/pnas.1217091110 PMID: 23959876; PubMed Central PMCID: PMCPMC4389630.

14. Rodrigues M, Kashiwabuchi F, Deshpande M, Jee K, Goldberg MF, Lutty GA. Dual-perspective analysis of vascular formations in sickle cell retinopathy. Birth Defects Orig Artic Ser. 2015; 57(15):6739–46. https://doi.org/10.1167/iovs.16-19513 PMID: 27951596; PubMed Central PMCID: PMCPMC5156513.

15. Montaner S, Sodhi A. Angiopoietin-like-4 as an Emerging Therapeutic Target for Diabetic Eye Disease. JAMA Ophthalmol. 2015; 133(12):1375–6. Epub 2015/10/16. https://doi.org/10.1001/jamaophthalmol.2015.3723 PMID: 26469243.

16. Montaner S, Sodhi A, Molinolo A, Bugge TH, Sawai ET, Damman O. Retinopathy of prematurity. Lancet. 2013; 382(9902):1445–57. https://doi.org/10.1016/S0140-6736(13)60179-6 PMID: 23782866; PubMed Central PMCID: PMCPMC4389630.

17. Rodigues M, Kashiwabuchi F, Deshpande M, Jee K, Goldberg MF, Lutty GA. Expression Pattern of HIF-1alpha and VEGF Supports Circumferential Application of Scatter Laser for Proliferative Sickle Retinopathy. Invest Ophthalmol Vis Sci. 2016; 57(15):6739–46. https://doi.org/10.1167/iovs.16-19513 PMID: 27951596; PubMed Central PMCID: PMCPMC5156513.

18. Hu K, Babapoor-Farrokhran S, Rodrigues M, Deshpande M, Puchner B, Kashiwabuchi F, et al. Hypoxia-inducible factor 1 upregulation of both VEGF and ANGPTL4 is required to promote the angiogenic phenotype in uveal melanoma. Oncotarget. 2016; 7(7):7816–28. https://doi.org/10.18632/oncotarget.6868 PMID: 26761211; PubMed Central PMCID: PMCPMC4884956.

19. Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampol HM, Shah ST, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994; 331(22):1480–7. https://doi.org/10.1056/NEJM199412013312203 PMID: 7526212.

20. Gross JG, Glassman AR, Jampol LM, Inusah S, Aiello LP, Antoszyk AN, et al. Panretinal Photocoagulation vs Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial. Jama. 2015; 314(20):2137–46. Epub 2015/11/14. https://doi.org/10.1001/jama.2015.15217 PMID: 26656927.

21. Babalola OE. Intravitreal bevacizumab (Avastin) associated with secondary hyphaema in a case of proliferative sickle cell retinopathy. BMJ Case Rep, 2010,2010. https://doi.org/10.1136/bcr.11.2009.2441 PMID: 22461855; PubMed Central PMCID: PMCPMC3029455.
22. Moshiri A, Ha NK, Ko FS, Scott AW. Bevacizumab presurgical treatment for proliferative sickle-cell retinopathy-related retinal detachment. Retin Cases Brief Rep. 2013; 7(3):204–5. Epub 2013/07/01. https://doi.org/10.1097/ICB.0b013e3182845d31 PMID: 25391106.

23. Shaikh S. Intravitreal bevacizumab (Avastin) for the treatment of proliferative sickle retinopathy. Indian J Ophthalmol. 2008; 56(3):259. Epub 2008/04/18. PMID: 18417840; PubMed Central PMCID: PMC2636113.

24. Siqueira RC, Costa RA, Scott IU, Cintra LP, Jorge R. Intravitreal bevacizumab (Avastin) injection associated with regression of retinal neovascularization caused by sickle cell retinopathy. Acta Ophthalmol Scand. 2006; 84(6):834–5. Epub 2006/11/07. https://doi.org/10.1111/j.1600-0420.2006.00779.x PMID: 17083555.

25. Bressler SB, Qin H, Melia M, Bressler NM, Beck RW, Chan CK, et al. Exploratory analysis of the effect of intravitreal ranibizumab or triamcinolone on worsening of diabetic retinopathy in a randomized clinical trial. JAMA Ophthalmol. 2013; 131(8):1033–40. Epub 2013/06/29. https://doi.org/10.1001/jamaophthal.2013.4154 PMID: 23807371; PubMed Central PMCID: PMC4162127.

26. Ip MS, Domalpally A, Sun JK, Ehrlich JS. Long-term effects of therapy with ranibizumab on diabetic retinopathy severity and baseline risk factors for worsening retinopathy. Ophthalmology. 2015; 122(2):367–74. Epub 2014/12/03. https://doi.org/10.1016/j.ophtha.2014.08.048 PMID: 25439595.